Lazard Asset Management’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
VCM
VPM
N
Lazard Asset Management's ADMA Position: Q1 2026 in Review
Lazard Asset Management reduced its ADMA Biologics (ADMA) stake by 41% in Q1 2026, selling an estimated $330K and leaving 29,757 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #1542.
Lazard Asset Management first reported a position in ADMA in Q4 2021 and has held it in 18 quarters since. The position peaked at $8.32M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.
- Lazard Asset Management held 29,757 shares of ADMA Biologics worth $268K as of Q1 2026.
- Lazard Asset Management sold 20,880 ADMA Biologics shares in Q1 2026, an estimated $330K.
- ADMA Biologics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1542 holding.
- Lazard Asset Management first reported a position in ADMA Biologics in Q4 2021 and has held it in 18 quarters since.
- Lazard Asset Management's ADMA Biologics position peaked at $8.32M in Q1 2025.
- 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.